The technology CMT is buying is used in the detection of human papillomavirus, which causes cervical cancer and sexually transmitted disorders. CMT is in the process of diversifying both the composition of its revenues and its product offering to secure its future revenues. And the technology acquisition continues a shift in focus from therapeutic products to diagnostic equipment. In vitro diagnostic equipment is expected to account for around 80% of total revenues in fiscal year 2009.
The deal comes a little under two months after...
¬ Haymarket Media Limited. All rights reserved.
